Overview

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-10-16

Target enrollment:

Participant gender:

Summary

This is a study to confirm the relative bioequivalence of sonelokimab administered subcutaneously via a prefilled syringe (PFS) or an autoinjector (AI) in healthy adult volunteers

Phase:

PHASE1

Details

Lead Sponsor:

MoonLake Immunotherapeutics AG

Treatments:

sonelokimab